POST Online Media Lite Edition


Impax adds J. Kevin Buchi to board of directors

Staff Writer |
Hayward, Ca., USA - November 29, 2016, Hayward, Ca., USA - Impax Laboratories, a specialty pharmaceutical company, announced that J. Kevin Buchi was appointed to the Impax board of directors.

Mr. Buchi currently serves as President, Chief Executive Officer and a member of the board of directors of TetraLogic Pharmaceuticals Corporation.

Prior to joining TetraLogic Pharmaceuticals in August 2013, Mr. Buchi served as Corporate Vice President of Global Branded Products at Teva Pharmaceutical Industries Limited from 2011 to May 2012.

Before joining Teva, he was Chief Executive Officer of Cephalon, Inc., which was acquired by Teva in October 2011.

Mr. Buchi joined Cephalon in 1991 and held various leadership positions, including Chief Financial Officer and Chief Operating Officer, before becoming Cephalon's Chief Executive Officer in December 2010.

In addition to being a director of TetraLogic Pharmaceuticals, Mr. Buchi has since 2013 served as a director of Benitec Biopharma Ltd., a NASDAQ listed biotechnology company headquartered in Australia.

He has extensive experience as a director having previously served on the board of a number of pharmaceutical companies including EPIRUS Biopharmaceuticals, Inc., Alexza Pharmaceuticals, Inc. and Forward Pharma A/S.


What to read next

Alexza Pharmaceuticals appoints J. Kevin Buchi to its board of directors
Cephalon: J. Kevin Buchi CEO and member of the board
Impax Asset Management Group appoints two directors